hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06348524, orgStudyIdInfo id: ferumoxytol_2015, briefTitle: Ferumoxytol-enhanced Magnetic Resonance Imaging, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-03, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Transmed Solutions, class: OTHER, descriptionModule briefSummary: There are no current alternatives to diagnostic contrast-requiring imaging for patients with an eGFR \<30mL/min due to the association of gadolinium-based imaging modalities to nephrogenic systemic fibrosis and iodinated contrast-induced kidney injury. Ferumoxytol-enhanced imaging may offer an alternative approach., conditionsModule conditions: Coronary Artery Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Ferumoxytol injection, outcomesModule primaryOutcomes measure: Detect the absence of ≥50% stenosis in the coronary artery tree, secondaryOutcomes measure: Detect stenosis in proximal and distal segments of the coronary artery tree, secondaryOutcomes measure: Compare ferumoxtyol enhanced magnetic resonance angiography with stress echocardiography, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06348498, orgStudyIdInfo id: TSL-TCM-JSP-Ⅰb, briefTitle: Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Tasly Pharmaceutical Group Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in patients with Chronic Heart Failure., conditionsModule conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Jia Shen Tablet, outcomesModule primaryOutcomes measure: Pharmacokinetic characteristic evaluation：Maximum observed plasma concentration (Cmax), primaryOutcomes measure: Plasma PK analysis: Time to reach peak or maximum observed concentration following drug administration (Tmax), primaryOutcomes measure: Plasma PK analysis: Area under curve at steady state (AUCss), secondaryOutcomes measure: NT-proBNP, secondaryOutcomes measure: 6-Minutes-Walking-Test (6MWT), secondaryOutcomes measure: Echocardiogram results, secondaryOutcomes measure: NYHA classification, secondaryOutcomes measure: AEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, city: Tianjin, state: Tianjin, country: China, contacts name: Yuhong Huang, role: CONTACT, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06348485, orgStudyIdInfo id: VGHTCCTC_NPCbleeding001, briefTitle: Massive Nasal Bleeding in Patients With NPC Received Curative RT, statusModule overallStatus: COMPLETED, startDateStruct date: 1994-12-01, primaryCompletionDateStruct date: 2019-04-30, completionDateStruct date: 2024-02-29, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Taichung Veterans General Hospital, class: OTHER, descriptionModule briefSummary: To investigate the incidence, predictive markers, and survival impact of massive nasal bleeding in nasopharyngeal carcinoma (NPC) patients who received curative radiotherapy (RT) with/without chemotherapy. A total of 1327 patients with previously untreated, biopsy-proven NPC, and no distant metastasis were retrospective reviewed. Investigators analyzed the occurrence rates of massive nasal bleeding between different characteristics and tried to identify important predictive factors. Investigators compared overall survival between patients with and without massive nasal bleeding by Kaplan-Meier method., conditionsModule conditions: Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1327, type: ACTUAL, armsInterventionsModule interventions name: Patients without massive nasal bleeding, interventions name: Patients with massive nasal bleeding, outcomesModule primaryOutcomes measure: Massive Nasal Bleeding Rate, secondaryOutcomes measure: Overall Survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taichung Veterans General Hospital, city: Taichung, zip: 407, country: Taiwan, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06348472, orgStudyIdInfo id: 0004-24-SHA, briefTitle: The Predictive Role of Immune-inflammatory Biomarkers and Their Interaction With the Oxytocin System in Trauma-related Psychotherapy Responsiveness, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2028-03-01, completionDateStruct date: 2028-03-01, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Shalvata Mental Health Center, class: OTHER, descriptionModule briefSummary: Despite a range of treatments for posttraumatic stress disorder (PTSD), only a small proportion of patients reach full symptomatic remission. Recent developments in the field of neuroscience have been providing compelling evidence to suggest that neurobiological determinants might influence not only the emergence of PTSD, but also its resistance to treatment. Immune-inflammation regulatory processes were found to be active during recovery from PTSD, potentially through interactive relationship with the oxytocin secretion system. This innovative longitudinal study aims to examine the role of inflammatory biomarkers and their interactive effect with the oxytocin (OT) system on the development of PTSD and on treatment response among patients with PTSD symptoms undergoing psychotherapy treatment. Patients (N = 100) suffering from trauma-related distress will be recruited from the trauma clinic in Shalvata Mental Health Center. Participants will be followed for 12 weeks of once-a-week psychotherapy sessions. They will be measured for endogenous OT level and cytokines levels in saliva before and after sessions 1, 6, and 12, and will complete psychotherapy outcome self-report questionnaires following each of these sessions., conditionsModule conditions: Posttraumatic Stress Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Oxytocin Secretion, primaryOutcomes measure: Inflammatory Response: IL-1β, primaryOutcomes measure: Inflammatory Response: IL-6, primaryOutcomes measure: Inflammatory Response: TNF-α, primaryOutcomes measure: Posttraumatic stress disorder symptoms, primaryOutcomes measure: Depression severity, primaryOutcomes measure: General anxiety symptoms, secondaryOutcomes measure: Psychological resilience, secondaryOutcomes measure: Working Alliance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shalvata Mental health Center, status: RECRUITING, city: Hod HaSharon, country: Israel, contacts name: Omer Sedoff, MA, role: CONTACT, email: omerse@clalit.org.il, geoPoint lat: 32.15934, lon: 34.8932, hasResults: False
protocolSection identificationModule nctId: NCT06348459, orgStudyIdInfo id: 18/010-E, briefTitle: Registry of Catheter Intervention in Pulmonary Embolism, acronym: RiTEP, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-09-18, primaryCompletionDateStruct date: 2029-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Hospital San Carlos, Madrid, class: OTHER, collaborators name: Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología, descriptionModule briefSummary: Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism., conditionsModule conditions: Pulmonary Embolism, conditions: Pulmonary Embolism Acute Massive, conditions: Pulmonary Embolism Acute, conditions: Pulmonary Embolism and Thrombosis, conditions: Pulmonary Thromboembolisms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: All cause-death, secondaryOutcomes measure: all cause-death, secondaryOutcomes measure: all cause-death, secondaryOutcomes measure: all cause-death, secondaryOutcomes measure: procedural success, secondaryOutcomes measure: in-hospital complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Clinico San Carlos, status: RECRUITING, city: Madrid, zip: 28040, country: Spain, contacts name: Pablo Salinas, MD, PhD, role: CONTACT, phone: +34913303000, email: salinas.pablo@gmail.com, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06348446, orgStudyIdInfo id: FY20-2963, briefTitle: Tacrolimus Exposure in Kidney Transplantation, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-02-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, collaborators name: Astellas Pharma Inc, descriptionModule briefSummary: Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation., conditionsModule conditions: Kidney Transplant Rejection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 12000, type: ESTIMATED, outcomesModule primaryOutcomes measure: relationship between time varying periodic mean of tacrolimus trough and a composite 1-year allograft outcomes, secondaryOutcomes measure: relationship between time varying periodic mean of tacrolimus trough level during 12-72 mo. post-transplant and 6-year composite allograft outcome, secondaryOutcomes measure: relationship between post-transplant time varying periodic mean tacrolimus trough level and severe infection, secondaryOutcomes measure: relationship between post-transplant time varying periodic mean tacrolimus trough level and cardiovascular event, secondaryOutcomes measure: relationship between post-transplant time varying periodic mean tacrolimus trough level and patient mortality, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Asan medical center, Seoul, Korea, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Young Hoon Kim, MD, role: CONTACT, phone: 82-10-2705-6998, email: kyh-001@hanmail.net, geoPoint lat: 37.566, lon: 126.9784, locations facility: Samsung medical center, Seoul, Korea, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Jae Berm Park, MD, role: CONTACT, phone: 82-10-8971-1953, email: jbparkmd@gmail.com, geoPoint lat: 37.566, lon: 126.9784, locations facility: Seoul St. Mary's hospital, Seoul, Korea, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Sun Cheol Park, MD, role: CONTACT, phone: 82-10-6310-2847, email: sun60278@catholic.ac.kr, geoPoint lat: 37.566, lon: 126.9784, locations facility: Severance hospital, Seoul, Korea, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: kyuha Hur, MD, role: CONTACT, phone: 82-10-2043-9947, email: KHHUH@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06348420, orgStudyIdInfo id: 2023-QILU-LU 03, briefTitle: Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment, acronym: ARMV, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2027-04-20, completionDateStruct date: 2027-08-13, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, collaborators name: Shandong University, descriptionModule briefSummary: The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs)., conditionsModule conditions: Gastroesophageal Reflux Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: anti-reflux mucosal valvuloplasty (ARMV), outcomesModule primaryOutcomes measure: The total score of the GERD-HRQL questionnaire, secondaryOutcomes measure: Number of Participants with PPI usage, secondaryOutcomes measure: Appearance of the mucosal flap, secondaryOutcomes measure: Presence of reflux esophagitis, secondaryOutcomes measure: Safety evaluation indicators, secondaryOutcomes measure: Total score of GERD GerdQ questionnaire, secondaryOutcomes measure: DeMeester score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06348407, orgStudyIdInfo id: 2024-BA-001, briefTitle: A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE), acronym: ESSENCE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Allergic asthma being the most widespread and easily identifiable phenotype, accounting for 60-80% of cases.Previous studies have reported that nearly 90% of patients with severe asthma were cases of allergic asthma, in which Immunoglobulin E (IgE) plays a critical role.Omalizumab was approved as an anti-IgE humanized monoclonal antibody for the treatment of patients with poorly controlled moderate-to-severe asthma, and was the first targeted drug used in the field of asthma treatment.The drug was launched in mainland China in August 2017.whereas,the clinical application experience, effects, and relevant data in the domestic population still lacking.The aim of this study was to observe the efficacy and safety of omalizumab, and to investigate whether baseline clinical characteristics and biomarkers can predicted response and adherence to treatment., conditionsModule conditions: Moderate to Severe Allergic Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: IgE monoclonal antibody, outcomesModule primaryOutcomes measure: Change in Asthma Control Test (ACT), primaryOutcomes measure: Global Evaluation of Treatment Effectiveness (GETE), secondaryOutcomes measure: Forced Expiratory Volume in 1 second（FEV1), secondaryOutcomes measure: FEV1/predicted%., secondaryOutcomes measure: Forced Vital Capacity （FVC）, secondaryOutcomes measure: FEV1/FVC., secondaryOutcomes measure: Number of Acute Exacerbations（AE）, secondaryOutcomes measure: Oral glucocorticoid dosage, secondaryOutcomes measure: Good adherence, secondaryOutcomes measure: Poor adherence, secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 90 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Linfu zhou, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210000, country: China, contacts name: Xuejun Zhang, Master, role: CONTACT, phone: 86+13704726254, email: zxj1301@163.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06348394, orgStudyIdInfo id: 023-318, briefTitle: Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion, acronym: ICETEE, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-12-14, primaryCompletionDateStruct date: 2025-12-14, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Baylor Research Institute, class: OTHER, descriptionModule briefSummary: This single-center, prospective, randomized study will evaluate the safety and feasibility of Intracardiac echocardiography (ICE)-guided Left atrial appendage closure (LAAC) when compared to the traditional Transesophageal echocardiography (TEE) approach., conditionsModule conditions: Left Atrial Appendage Closure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Prospective, randomized, parallel controlled, open-label, single center study, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 444, type: ESTIMATED, armsInterventionsModule interventions name: Intracardiac Echocardiography, outcomesModule primaryOutcomes measure: Procedural success following implantation of the left atrial appendage occlusion (LAAO) device., secondaryOutcomes measure: Periprocedural complications, secondaryOutcomes measure: Procedural characteristics, secondaryOutcomes measure: Patient satisfaction, secondaryOutcomes measure: Periprocedural complications, secondaryOutcomes measure: Periprocedural complications, secondaryOutcomes measure: Procedural characteristics, secondaryOutcomes measure: Procedural characteristics, secondaryOutcomes measure: Procedural characteristics, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Baylor Scott and White Heart Hospital, city: Plano, state: Texas, zip: 75093, country: United States, geoPoint lat: 33.01984, lon: -96.69889, hasResults: False
protocolSection identificationModule nctId: NCT06348381, orgStudyIdInfo id: IS24030, briefTitle: Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Shanghai Chest Hospital, class: OTHER, descriptionModule briefSummary: Analyze the correlation between the conformity of the anatomy (based on endoscopic examination) and postoperative anastomotic fistula and anastomotic stenosis; establish an anastomotic classification; and construct a predictive model combined with perioperative-related test indicators to provide more accurate risk assessment for clinical practice. Analyze the natural recovery process of postoperative recurrent laryngeal nerve injury in esophageal cancer by tracking vocal cord movement (based on endoscopic examination) and hoarseness symptoms; combined with perioperative related surgical and laboratory indicators, identify the relevant risk factors associated with delayed recovery of recurrent laryngeal nerve injury., conditionsModule conditions: Esophageal Neoplasm, conditions: Anastomotic Leak, conditions: Recurrent Laryngeal Nerve Injuries, conditions: Anastomotic Stenosis, conditions: Endoscopic Evaluation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: anastomotic leak, primaryOutcomes measure: anastomotic stenosis, primaryOutcomes measure: laryngeal nerve injury, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Chest Hospital, Shanghai Jiao Tong University, status: RECRUITING, city: Shanghai, zip: SH 21, country: China, contacts name: Zhigang Li, Doctor, role: CONTACT, phone: 86-18930619260, email: zhigang.li@shchest.org, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06348368, orgStudyIdInfo id: Soh-Med-23-01-29, briefTitle: Refractive and Corneal Topographic Characteristics in Upper Egypt Children With High Cylinder, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-01-30, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: Refractive and Corneal Topographic Characteristics in upper Egypt children with high cylinder: A cross sectional study, conditionsModule conditions: Corneal Ectasia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 4000, type: ACTUAL, armsInterventionsModule interventions name: Pentacam and autorefractometry, outcomesModule primaryOutcomes measure: Values anterior and posterior corneal elevation values by pentacam., eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Elshimaa A.Mateen, city: Sohag, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False